Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?

por Steenbruggen, Tessa G, Linn, Sabine C, Rodenhuis, Sjoerd, Sonke, Gabe S
Publicado 2015

Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes

por Kruger, Dinja T., Opdam, Mark, Sanders, Joyce, van der Noort, Vincent, Boven, Epie, Linn, Sabine C.
Publicado 2020

Scenario drafting to anticipate future developments in technology assessment

por Retèl, Valesca P, Joore, Manuela A, Linn, Sabine C, Rutgers, Emiel JT, van Harten, Wim H
Publicado 2012

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen

por de Vries Schultink, Aurelia H. M., Zwart, Wilbert, Linn, Sabine C., Beijnen, Jos H., Huitema, Alwin D. R.
Publicado 2015

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences

por Kruger, Dinja T., Beelen, Karin J., Opdam, Mark, Sanders, Joyce, van der Noort, Vincent, Boven, Epie, Linn, Sabine C.
Publicado 2018

Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation

por de Jong, Vincent M. T., Pruntel, Roelof, Steenbruggen, Tessa G., Bleeker, Fonnet E., Nederlof, Petra, Hogervorst, Frans B. L., linn, Sabine C.
Publicado 2022

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy

por Beelen, Karin, Hoefnagel, Laurien DC, Opdam, Mark, Wesseling, Jelle, Sanders, J, Vincent, Andrew D, van Diest, Paul J, Linn, Sabine C
Publicado 2014

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative a...

por Schouten, Philip C., Dackus, Gwen M. H. E., Marchetti, Serena, van Tinteren, Harm, Sonke, Gabe S., Schellens, Jan H. M., Linn, Sabine C.
Publicado 2016

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy

por van Aken, Evert S. M., Beeker, Aart, Houtenbos, Ilse, Pos, Floris J., Linn, Sabine C., Elkhuizen, Paula H. M., de Jong, Monique C.
Publicado 2021

Lack of Genomic Heterogeneity at High-Resolution aCGH between Primary Breast Cancers and Their Paired Lymph Node Metastases

por Vollebergh, Marieke A., Klijn, Christiaan, Schouten, Philip C., Wesseling, Jelle, Israeli, Danielle, Ylstra, Bauke, Wessels, Lodewyk F.A., Jonkers, Jos, Linn, Sabine C.
Publicado 2014

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer

por Kruger, Dinja T., Alexi, Xanthippi, Opdam, Mark, Schuurman, Karianne, Voorwerk, Leonie, Sanders, Joyce, van der Noort, Vincent, Boven, Epie, Zwart, Wilbert, Linn, Sabine C.
Publicado 2019

PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane

por Kruger, Dinja T., Opdam, Mark, van der Noort, Vincent, Sanders, Joyce, Nieuwenhuis, Michiel, de Valk, Bart, Beelen, Karin J., Linn, Sabine C., Boven, Epie
Publicado 2020

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation

por Verbeek, Joost G. E., de Jong, Vincent M. T., Wijnja, Hanna M., Jager, Agnes, Linn, Sabine C., Retèl, Valesca P., van Harten, Wim H.
Publicado 2023

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care

por van der Meijde, Elisabeth, van den Eertwegh, Alfons J. M., Linn, Sabine C., Meijer, Gerrit A., Fijneman, Remond J. A., Coupé, Veerle M. H.
Publicado 2016

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer

por Dackus, Gwen M. H. E., Jóźwiak, Katarzyna, van der Wall, Elsken, van Diest, Paul J., Hauptmann, Michael, Siesling, Sabine, Sonke, Gabe S., Linn, Sabine C.
Publicado 2020

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients

por Dackus, Gwen M H E, Jóźwiak, Katarzyna, Sonke, Gabe S, van der Wall, Elsken, van Diest, Paul J, Siesling, Sabine, Hauptmann, Michael, Linn, Sabine C
Publicado 2021

Immune landscape of breast tumors with low and intermediate estrogen receptor expression

por Voorwerk, Leonie, Sanders, Joyce, Keusters, Milou S., Balduzzi, Sara, Cornelissen, Sten, Duijst, Maxime, Lips, Esther H., Sonke, Gabe S., Linn, Sabine C., Horlings, Hugo M., Kok, Marleen
Publicado 2023

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer

por Lips, Esther H., Benard-Slagter, Anne, Opdam, Mark, Scheerman, Caroline E., Wesseling, Jelle, Hogervorst, Frans B. L., Linn, Sabine C., Savola, Suvi, Nederlof, Petra M.
Publicado 2020

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites

por Jager, Nynke GL, Koornstra, Rutger HT, Vincent, Andrew D, van Schaik, Ron HN, Huitema, Alwin DR, Korse, Tiny M, Schellens, Jan HM, Linn, Sabine C, Beijnen, Jos H
Publicado 2013

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Rep...

por Szijgyarto, Zsolt, Flach, Koen D., Opdam, Mark, Palmieri, Carlo, Linn, Sabine C., Wesseling, Jelle, Ali, Simak, Bliss, Judith M., Cheang, Maggie Chon U., Zwart, Wilbert, Coombes, R. Charles
Publicado 2019